Title: Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic.
Journal: Archives of medical research 20100801
Title: Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents.
Journal: European journal of gastroenterology & hepatology 20081201
Title: Hypocholesterolemic effects of fatty acid bile acid conjugates (FABACs) in mice.
Journal: Archives of biochemistry and biophysics 20080301
Title: ABCA1-dependent but apoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs).
Journal: The Biochemical journal 20060615
Title: New targets in and potential treatments for cholesterol gallstone disease.
Journal: Current opinion in investigational drugs (London, England : 2000) 20060401
Title: Faecal sterol output is increased by arachidyl amido cholanoic acid (Aramchol) in rats.
Journal: Biochemical Society transactions 20040201
Title: Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC).
Journal: Hepatology (Baltimore, Md.) 20030801
Title: Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice.
Journal: Lipids 20011001
Title: Safadi R, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1.
Title: Iruarrizaga-Lejarreta M, et al. Role of Aramchol in steatohepatitis and fibrosis in mice. Hepatol Commun. 2017 Nov;1(9):911-927.
